Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Sanghuangyin for peri-interventional liver protection in primary liver cancer
ChiCTR2400085111Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2024
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sanghuangyin in hepatocellular carcinoma (HCC) and acute liver failure (ALF) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Liver function indices and Serological indicators of liver fibrosis. Planned start May 2024; status: not yet recruiting.
02
Drugs
Sanghuangyin
03
Conditions
hepatocellular carcinoma (HCC)acute liver failure (ALF)
Beyond the preview
Go deeper on ChiCTR2400085111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085111.